Pasithea Therapeutics Corp. Common Stock
Veridion Score
Composite trend over time
Why is KTTA moving today?
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KTTA.
KTTA insider activity
Pasithea Therapeutics Corp. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for KTTA.
KTTA contract awards, year to date.
Public federal awards linked to this ticker.
KTTA lobbying filings, year to date.
Registered lobbying filings matched to Pasithea Therapeutics Corp. Common Stock.